Posts

People will die: End of NIH grants guts work between academics and companies to counter next pandemic

on

Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer

on

Vertexs second-generation diabetes cell therapy fails early-stage study

on

Biotech Restructuring and European Regulatory Setbacks

on

Lilly's Lepodisiran Shows Durable Lipoprotein(a) Reduction in Phase 2 Trial

on

Beyond Black Box: How Data-Driven AI Is Transforming RNA Medicine Development

on

FDA Shakeup: Peter Marks' Resignation Rattles Biotech Industry

on

How the world's biggest pharma and biotech companies paid their typical worker in 2023

on

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

on

FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray for PSVT

on

CHMP recommends seven label expansions and one new approval, rejects Lilly Alzheimer's drug

on

BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody

on

BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific

on

Arbutus Down to Core Team After Laying Off More Than Half of Staff

on

Merck's Injectable Keytruda Shows Promising Results in Pivotal Trial

on

Equillium's pivotal GvHD study of anti-CD6 antibody comes up short

on

FDA to Decide on Merck's Subcutaneous Keytruda in September 2025

on

HHS Overhaul: RFK Jr. Cuts 20,000 Jobs in Major Restructuring

on

Galatea Bio's $25M Funding Boost for Global Biobank and AI-Driven Genomic Research

on

Chiesi unveils 430M investment to revitalize Italian production site for inhaler, biologics manufacturing

on

Nkarta lays off 3rd of staff, including CFO, to fund autoimmune CAR NK program

on

Drugmakers fear Trump tariffs will drive up manufacturing costs, hurt medicine access: BIO survey

on

FDAs policy, communications staff likely to be among agencys 3,500 staff cuts

on

Alcon Secures Control of Aurion Biotech in Strategic Takeover

on

Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR

on

GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?

on

Wave Life Sciences' WVE-N531 Shows Promise in Duchenne Muscular Dystrophy Treatment

on

FDA clears Exelixis' TKI for neuroendocrine tumours

on

Trump Tariffs Could Delay Regulatory Filings for Half of Biotech Companies

on

Kaken Secures Japanese Rights for Alumis' Novel TYK2 Inhibitor ESK-001

on

J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca's Tagrisso

on